Peptide raves and group buys: how self-injection went social

What the scene looks like

In January 2026, The New York Times described how gray-market peptides had spread through parts of the San Francisco tech world: hacker houses, start-up offices, backyard parties where founders compared sources, and events sponsored by suppliers. One, held at Frontier Tower on December 13, 2025, combined a DJ playing techno in front of projected chemical structures with a workshop on mixing your own peptides and a cyberpunk dress code. At a New York biohacker meetup, an investor told the paper, people brought something new each week and everyone injected it (news report) ¹.

The Times traced the phrase "Chinese peptides" to a Fourth of July party in a San Francisco backyard, where an AI founder mentioned buying cheap drugs directly from manufacturers in China and a crowd gathered to swap sources. A guest who hosts a tech-culture podcast posted that, as far as he could tell, the elite all had a peptide dealer in China, and the phrase became a meme (news report) ¹.

The products being passed around ranged from GLP-1 weight-loss drugs to compounds with little or no human evidence: BPC-157 and TB-500 for injuries, epitalon for sleep, oxytocin, melanotan and retatrutide, a weight-loss drug still in clinical trials. Several of those have entries here, and our entries show how thin the human evidence is for most of them: BPC-157 and TB-500 rest mainly on animal studies, and retatrutide is unapproved anywhere.

The numbers behind the trend come from trade and advertising data. According to US customs figures analysed by the Times, imports of hormone and peptide compounds from China roughly doubled, from $164 million in the first three quarters of 2024 to $328 million in the same period of 2025, a figure that also includes supply to compounding pharmacies. A firm that monitors online pharmaceutical advertising told the paper that ads for unauthorised peptide formulations grew nearly eightfold between 2022 and 2024 (news report) ¹.

Why it went social

Price is the first reason. The Times reported in January 2026 that "research use" versions of semaglutide and tirzepatide sold for about a fifth of the cost of prescription products, and that kits ordered directly from manufacturers in China cost $50 to $100, roughly a tenth of what regulated labs charge (news report) ¹. The second is access: for most of these compounds there is no prescription route at all, because no company has run the trials needed for approval.

The third is culture. Users described learning about peptides from friends, Reddit threads, podcasts and chatbots, and several founders compared their tolerance for untested compounds with their tolerance for business risk. A supplier told the paper that use spread through companies from the top down, and that the typical customer was now far from the tech elite. Physicians quoted in the piece called the practice unfounded and reckless, pointing out that the evidence most users would need, randomised placebo-controlled trials published independently of the seller, does not exist for most of these peptides (news report) ¹.

Social settings change the risk in a specific way. At a party or meetup, a compound arrives with a personal endorsement rather than a label, and a demonstration replaces training. Our article on what "research use only" means explains why the label on these vials is a legal disclaimer rather than a description of how they are used.

How a group buy works

A group buy is a collective order. An organiser in a messaging-app group collects money from members, orders a quantity of a compound from an overseas manufacturer at bulk prices, splits the shipment, and sets aside part of the pot to send a sample to an analytical laboratory. The appeal is that testing, which can cost a few hundred dollars per sample, becomes affordable when its cost is shared. One founder the Times interviewed in January 2026 paid $250 per sample to have kits tested at a laboratory in the Czech Republic (news report) ¹.

Groups vary widely in how carefully they work. Some publish every test result, including failures; others share only the results that flatter their chosen supplier, or accept certificates supplied by the seller. The structure also concentrates risk: one contaminated batch, split among dozens of buyers, reaches dozens of people. We do not name or link any group, supplier or laboratory, in line with our policy of linking to no vendor.

What independent tests have found

The most careful public study of gray-market GLP-1 products tested semaglutide bought from illegal online pharmacies in 2023. Of six test purchases, the three injection pens ordered never arrived; the three vials that did were judged probably substandard and falsified. Their purity was between 7.7% and 14.4% against the 99% claimed on the label, while the measured amount of semaglutide was 29% to 39% above what the label stated, and bacterial endotoxin was detected in every vial, although no live microorganisms were found (market surveillance study) ².

Other products are worse. When anti-doping chemists analysed 14 products sold as ACE-031, a muscle-building decoy receptor, none contained it: twelve held a different, full-length receptor protein mixed with many other proteins (laboratory analysis) ³. Of 17 products labelled "follistatin 344", only nine contained follistatin at all, and some of the others contained different growth-promoting peptides (laboratory analysis) ⁴. A co-founder of a peptide-testing start-up told New York magazine that they had seen vials labelled semaglutide that held retatrutide, or no peptide at all (news report) ⁵. Many shipments arrive with a certificate of analysis already attached, issued by a testing company on the seller's behalf, which is precisely why groups pay for their own tests (news report) ⁵. Our article on retatrutide testing failures collects more of these results.

What testing cannot tell you

Group testing is a genuine improvement on trusting a label, but a certificate of analysis answers narrow questions. A standard test measures identity, usually by mass spectrometry, and purity, usually by HPLC, in the one sample sent. It does not establish that the rest of the batch matches, that the vial is sterile, or how much endotoxin it carries unless those tests are specifically ordered. The semaglutide study above found endotoxin in every vial, the kind of contaminant a purity test does not look for ².

It also cannot tell you whether the compound does anything. A perfectly pure vial of a peptide with no human trials is still a peptide with no human trials. And certificates are easy to fake or reuse; our guide to spotting a fake certificate in 60 seconds and the COA decoder walk through what a genuine report should contain.

The harm-reduction gaps

Harm-reduction services for other drugs grew around a few known substances and known risks. Peptides do not fit that model. There are dozens of compounds, most with no human dosing data, sold as powders that buyers dissolve and inject themselves. The Times reported that two women were hospitalised in July 2025 with swollen tongues, breathing difficulty and a racing heart after peptide injections at an anti-aging festival in Las Vegas; what they were given was not established (news report) ¹.

The gaps are concrete. Doses circulate by word of mouth rather than from studies, because for most of these compounds no human dose has been tested. Sterile preparation is taught, if at all, at events like the one described above. Allergic reactions, infections at injection sites and interactions with prescribed medicines go unrecorded, so no one can say how common they are. And reporting a problem to a doctor means admitting to using an unapproved product, which some users avoid.

Regulators' positions are clear even if enforcement is not. The FDA has warned that many of these peptides pose serious safety risks from impurities and immune reactions and has barred pharmacies from compounding several of them; personal possession is not itself illegal, according to the Times' reporting (news report) ¹. Our regulatory tracker follows each compound's status.

Who is actually using them

The tech-party image is only part of the picture. The supplier interviewed by the Times said early adopters came from tech because of their appetite for risk, but described his average customer as closer to a coffee-shop worker than a founder. A concierge physician in San Francisco reported a marked rise in peptide use during 2025, especially among young men in tech (news report) ¹.

Motives differ, and so does openness about them. People using peptides for productivity, sleep or recovery spoke to the Times on the record; people using GLP-1 drugs to lose weight more often asked not to be named, which the reporter read as a sign of greater stigma around weight. One founder said she had taken prescription GLP-1s for nearly two years and lost weight, but with depressive swings, and still felt the benefits outweighed the risks under professional pressure to look good on camera (news report) ¹.

A third group is people stretching an approved drug into unapproved territory. The Times described users microdosing GLP-1 drugs, taking amounts well below the labelled doses, in the hope of curbing drinking, gaming or online shopping. No clinical trial supports this (news report) ¹, and our entries on semaglutide and its relatives record the doses that were actually tested.

Why endotoxin matters

Endotoxin is a component of the outer wall of many bacteria. It survives the processes that kill the bacteria themselves, so a vial can be free of live microbes and still contain it, as every vial in the semaglutide study did ². Injected, endotoxin can trigger fever, chills and inflammation, and at high enough levels a dangerous drop in blood pressure. That is why injectable medicines are made under sterile conditions and tested against strict endotoxin limits before release.

A powder made in a facility not held to those standards, dissolved in a kitchen and injected repeatedly, sidesteps every one of those safeguards. Group testing can add an endotoxin test, but it costs extra, and only some groups order it. A purity certificate on its own says nothing about it.

The politics around it

The culture has a political edge. The Times noted that Robert F. Kennedy Jr., now Secretary of Health and Human Services, pledged in October 2024 to end what he called suppression of peptides, after the FDA under the previous administration took enforcement action against some sellers. As of the paper's reporting, the new administration had not moved to deregulate peptides beyond GLP-1 drugs, and the department declined to comment on future policy (news report) ¹. Some users said they welcomed a lighter regulatory touch; a Harvard expert on drug regulation quoted in the same piece countered that the evidence for most of these compounds is essentially absent.

Formal review has continued since. Our report on the July 2026 Pharmacy Compounding Advisory Committee meeting covers how FDA's advisers voted on seven peptides that compounding pharmacies want to use: six recommended, against the agency staff's advice, and one rejected. What the FDA does with those votes matters most to anyone hoping for a regulated supply.

If something goes wrong

Some warning signs need emergency care whatever was injected: swelling of the lips, tongue or throat, difficulty breathing, a racing heart or fainting soon after an injection, which can mean a severe allergic reaction like the ones reported in Las Vegas; or fever, spreading redness, heat and pain around an injection site, which can mean infection. Fever and chills within hours of an injection can also come from endotoxin in the product.

Taking the vial or its label to the emergency department helps clinicians, even if the label is unreliable, and so does saying plainly what was taken and when. Doctors are there to treat the reaction, not to judge the choice, and leaving out an unapproved injection can lead them to the wrong diagnosis. In the US, Poison Control (1-800-222-1222) can advise on suspected reactions at any hour.

Questions worth asking before you join

• Is there a published human trial of this compound, and what did it find?
• Was the test done on this batch, by a laboratory the seller does not control, and does it include sterility and endotoxin?
• Who decides the dose, and on what evidence?
• Will the doctor who treats you if something goes wrong know what you took?

How it adds up (as of October 4, 2026)

Peptide self-injection has become a social activity, spread through parties, meetups and group chats, and fuelled by price and by compounds that have no legal route to patients. Group buys make laboratory testing affordable, and the tests they pay for have exposed products at a fraction of their claimed purity, contaminated with endotoxin, or containing the wrong molecule. But a clean certificate covers identity and purity in one sample. It does not establish sterility, the right dose, or that a compound is safe or effective in people, and for most peptides passed around these circles that evidence does not exist. The safest question to bring to any group, party or seller is the plainest one: what human study shows this works, and at what dose?

Frequently asked questions

What is a peptide group buy?

A collective order organised in a messaging group: members pool money to buy a compound in bulk from an overseas manufacturer and to pay for laboratory testing of a sample.

What is a peptide rave?

A party combining music with peptide use or instruction. The New York Times described one in San Francisco in December 2025, sponsored by suppliers, that included a mix-your-own peptides workshop.

Does third-party testing make gray-market peptides safe?

No. A standard test checks identity and purity in one sample. It does not establish sterility, endotoxin levels, correct dosing or that the compound is safe or effective in people.

What have tests of gray-market peptides found?

Semaglutide vials at 7.7-14.4% purity with endotoxin in every sample, products sold as ACE-031 that contained none, and 'follistatin 344' products of which only about half contained follistatin.

Is it legal to buy research-use-only peptides?

Sellers may not market them for human use, and the FDA has barred pharmacies from compounding several. Personal possession is generally not illegal in the US, but rules differ by compound and country.

Related on Grey Peptides

• What "research use only" means
• Spot a fake COA in 60 seconds
• Retatrutide testing failures
• COA decoder
• Regulatory tracker

Sources

1. Sun, J. "'Chinese Peptides' Are the Latest Biohacking Trend in the Tech World." The New York Times, January 3, 2026 (syndicated text read October 4, 2026).
2. Ashraf, A. R., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 26, e65440. PMID: 39509151
3. Reichel, C., et al. (2025). Gel Electrophoretic Detection of Black Market ACE-031. Drug Test Anal, 17(10), 1934-1946. PMID: 40312924
4. Reichel, C., et al. (2019). Detection of black market follistatin 344. Drug Test Anal, 11(11-12), 1675-1697. PMID: 31758732
5. Marcus, E., reporting in New York magazine's newsletter, "Should We All Be Shooting Ourselves Full of Peptides?" (2026), including an interview with a co-founder of a peptide-testing start-up; read October 4, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.